Kenvue Inc. (NYSE:KVUE) Shares Acquired by Amundi

Amundi boosted its position in Kenvue Inc. (NYSE:KVUE) by 4.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 7,506,253 shares of the company’s stock after buying an additional 327,688 shares during the period. Amundi’s holdings in Kenvue were worth $158,577,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC boosted its position in Kenvue by 22.4% during the fourth quarter. Larson Financial Group LLC now owns 23,040 shares of the company’s stock worth $492,000 after acquiring an additional 4,210 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Kenvue by 5.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 446,047 shares of the company’s stock worth $9,523,000 after purchasing an additional 23,381 shares in the last quarter. Banco Santander S.A. acquired a new stake in Kenvue in the fourth quarter valued at approximately $244,000. Camden National Bank acquired a new position in Kenvue in the 4th quarter worth $252,000. Finally, Bradyco Inc. acquired a new stake in Kenvue during the 4th quarter valued at approximately $240,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

KVUE has been the topic of several research analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Barclays reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Citigroup lowered their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $23.75.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.46 on Monday. The company has a market cap of $44.83 billion, a price-to-earnings ratio of 44.25, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a 50 day simple moving average of $21.64 and a 200 day simple moving average of $22.33.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.